HIV pre-exposure prophylaxis

Citation metadata

Date: Oct. 21, 2014
From: CMAJ: Canadian Medical Association Journal(Vol. 186, Issue 15)
Publisher: CMA Impact Inc.
Document Type: Article
Length: 650 words
Lexile Measure: 2100L

Document controls

Main content

Article Preview :

HIV pre-exposure prophylaxis (PrEP) is the regular use of antiretroviral medication by HIV-negative individuals to prevent HIV infection

Currently, PrEP refers to prophylactic daily oral use of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), a formulation that is indicated in Canada for the treatment of HIV infection. Although licensed only in the United States for PrEP, this formulation is used off label in Canada for carefully selected and monitored individuals who are at high risk of HIV infection, based on expert clinician judgment. Those at high risk include men who have sex with men and who have frequent unprotected anal intercourse.

PrEP is efficacious in the prevention of HIV, with adherence being the critical determinant of effectiveness

Randomized controlled trials of PrEP have found reductions of 44%-75% in HIV incidence among men who have sex with men, heterosexual people and people using injection drugs. (1-4) Pharmacodynamic modeling suggests efficacy above 99% if PrEP is taken daily. (5) A trial of intermittent dosing, as well as...

Source Citation

Source Citation   

Gale Document Number: GALE|A386437128